Analyse the changes in Saliva in pyorrhea patient after treated by scaling Therapy

Not Applicable

Not yet recruiting

• Conditions: Other infectious disease,

• Registration Number: CTRI/2023/12/060727
• Lead Sponsor: Dr Vivek Kanjibhai Bhesaniya

Brief Summary

Periodontitis is one of the most prevalent oral diseases in the world. Approximately 5–20% of adults worldwide suffer from severe periodontitis which may lead to tooth loss. Biomarkers found in saliva can be evaluated to check for disease activity. Visfatin is a pre-B cell colony enhancing factor, a newly discovered adipokine released from adipose tissue, macrophages, and leukocytes. Aspartate aminotransferase  (AST) is an enzyme that can be found in cells all over the body and there is a direct relation between AST level and quantity of tissue impairment. This biomarker will provides a safe, and non-invasive approach for periodontal disease detection, and possesses a high potential to revolutionize the next generation of diagnostics. Thus  , the aim of this study was to evaluate the role of visfatin and Aspartate aminotransferase as best reliable diagnostic and prognostic biomarkers in oral diseases like periodontitis .

Detailed Description

Not available

Study Timeline

• Last Update Posted: 2023-12-21
• Study Start: 2024-01-02

Recruitment & Eligibility

• Status: Not Yet Recruiting
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

• Male and female patients of age groups 18 to 70 years.
• Minimum 20 teeth should be present.
• Patient diagnosed as Stage-II or Stage-III periodontitis.
• Systemically healthy patients.
• Patients ready to comply fully and willing to give consent form the final evaluation.
• Patients having ability to maintain optimum oral hygiene.

Exclusion Criteria

• Patients with systemic diseases.
• Smoking and alcoholism 3.
• Teeth no less than 20.
• Patients on antibiotics and anti-inflammatory drugs since 6 months.
• Pregnant or lactating females.
• Patients undergoing orthodontic treatment.
• Those who have undergone periodontal surgical treatment with in the last 6 months 8.
• Patient with obesity (BMI- more or equal to 30).

Study & Design

• Study Type: PMS
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Levels of Salivary Visfatin and	1st measurement at baseline and 2nd measurement at 4 weeks after Phase - I Periodontal therapy
Aspartate Aminotransferase	1st measurement at baseline and 2nd measurement at 4 weeks after Phase - I Periodontal therapy

Secondary Outcome Measures

Name	Time	Method
1) Probing pocket depth	2) Clinical attachment level

Trial Locations

Locations (1)

Government dental college and hospital - Nagpur; 🇮🇳 Nagpur, MAHARASHTRA, India

Government dental college and hospital - Nagpur

🇮🇳Nagpur, MAHARASHTRA, India

Dr Vivek Kanjibhai Bhesaniya

Principal investigator

7984960804

vivekbhesaniya7@gmail.com